I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Michael Patrick Boyle, M.D.
Expertise: Cystic Fibrosis, Lung Transplant, Pulmonary Disease and Critical Care Medicine
Research Interests: CFTR Modulators; Cystic Fibrosis Clinical Trials; Difficult to Treat Infections in Cystic Fibrosis
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Dr. Michael Boyle is an Adjunct Professor of Medicine at the Johns Hopkins University School of Medicine. His areas of expertise include adult cystic fibrosis care and research, lung transplantation and pulmonary diseases.
Dr. Boyle founded and then directed the Johns Hopkins Adult Cystic Fibrosis Program from 1999 to 2015 at the Johns Hopkins Cystic Fibrosis Center. He is now Senior Vice President for Therapeutics Development at the U.S. Cystic Fibrosis Foundation and Adjunct Johns Hopkins faculty member. His research is focused on clinical trials for the development of new cystic fibrosis therapies.
Dr. Boyle completed all of his medical training at Johns Hopkins including fellowship in pulmonary and critical care medicine before joining the Johns Hopkins faculty in 1999. He is internationally known both for his clinical research in CFTR modulators and for his work to improve care for adults with cystic fibrosis. While at Johns Hopkins he has received numerous honors including the American Lung Association’s George Comstock Career Achievement Award, American Federation of Clinical Research Achievement Award, “Patient’s Choice Award”, “Best Teacher”, and “Best Doctors in America”.
Departments / Divisions
- Medicine - Pulmonary and Respiratory
Centers & Institutes
- MD, Johns Hopkins University School of Medicine (1991)
- Johns Hopkins University School of Medicine / Internal Medicine (1994)
- Johns Hopkins University School of Medicine / Pulmonary and Critical Care Medicine (1999)
- American Board of Internal Medicine / Pulmonary Disease (1999)
Research & Publications
Dr. Boyle is internationally known for his clinical research in both CFTR modulators and difficult to treat lung infections. He has been the principal investigator for international clinical trials of CFTR modulator therapies which resulted in approval of new therapies for individuals with cystic fibrosis.
Selected PublicationsView all on Pubmed
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 373:220-31, 2015. PMID: 25981758
Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D. on behalf of the VX09-809-102 Study Group. Randomised Trial of Combined CFTR Corrector and Potentiator Therapy in F508del-CFTR Cystic Fibrosis. The Lancet – Respiratory Medicine. 2: 527-38, 2014. PMID: 24973281
Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association of Respiratory Tract Methicillin-Resistant Staphylococcus Aureus and Survival in Cystic Fibrosis. JAMA 303:2386-92, 2010. PMID: 20551409
Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent Methicillin-resistant Staphylococcus Aureus and Rate of FEV1 Decline in Cystic Fibrosis. Am J Respir Crit Care Med 178:814-821; 2008. PMID: 18669817
Boyle MP, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS. Key Findings of the Cystic Fibrosis Foundation's U.S. Clinical Practice Benchmarking Project. BMJ Quality and Safety. 23:15-22, 2014. PMID: 24608546
Contact for Research Inquiries
1830 E. Monument Street, 5th floor
Division of Pulmonary and Critical Care Medicine
Baltimore, MD 21205 map
Activities & Honors
- Best Doctors in America
- Alpha Omega Alpha (AOA), Johns Hopkins Chapter, 2006
- Senior Vice President of Therapeutics Development, Cystic Fibrosis Foundation, 2015